Clincosm LogoSign in Get a demo

recurrent acute myeloid leukemia

Showing 51 - 66 of 66
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Houston (Azacitidine,

Recruiting
  • Acute Myeloid Leukemia
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Nov 16, 2021

Blasts 10 Percent or More of Bone Marrow Nucleated Cells, Chronic Myelomonocytic Leukemia-2, High Grade Malignant Tumor Trial in

Completed
Has Results
  • Blasts 10 Percent or More of Bone Marrow Nucleated Cells
  • +8 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 11, 2021

Acute Myeloid Leukemia, Myeloid Leukemia, Recurrent Acute Myeloid Leukemia Trial in Houston (Biopsy, Biospecimen Collection,

Recruiting
  • Acute Myeloid Leukemia
  • +2 more
  • Biopsy
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 9, 2021

Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-MLL, Leukemia Cutis, Recurrent Acute Myeloid Leukemia Trial in New York

Completed
Has Results
  • Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-MLL
  • +3 more
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Aug 11, 2021

Acute Myeloid Leukemia, Hematopoietic and Lymphoid System Tumor, Myelodysplastic Syndrome Trial in United States (Azacitidine,

Recruiting
  • Acute Myeloid Leukemia
  • +5 more
  • Boston, Massachusetts
  • +3 more
Jun 30, 2021

Allogeneic Hematopoietic Stem Cell Transplant Recipient, Myeloproliferative Tumor, Recurrent Acute Lymphoblastic Leukemia Trial

Completed
  • Allogeneic Hematopoietic Stem Cell Transplant Recipient
  • +10 more
  • Ipilimumab
  • +2 more
  • Duarte, California
  • +12 more
Jun 23, 2021

Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Canada, United States (Enasidenib, Enasidenib

Recruiting
  • Recurrent Acute Myeloid Leukemia
  • Refractory Acute Myeloid Leukemia
  • Birmingham, Alabama
  • +17 more
Jun 21, 2021

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute

Recruiting
  • Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
  • +3 more
  • Gemtuzumab Ozogamicin
  • Liposome-encapsulated Daunorubicin-Cytarabine
  • Houston, Texas
    M D Anderson Cancer Center
Jun 2, 2021

Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Recurrent Myeloproliferative Tumor Trial in Chicago

Not yet recruiting
  • Recurrent Acute Myeloid Leukemia
  • +4 more
  • Chicago, Illinois
    Northwestern University
Mar 26, 2021

Blasts Under 5 Percent of Peripheral Blood White Cells, Bone Marrow Blasts Decreased by 50 Percent or More Compared to

Withdrawn
  • Blasts Under 5 Percent of Peripheral Blood White Cells
  • +4 more
  • Buffalo, New York
  • +1 more
Mar 8, 2021

Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Houston (Alvocidib Hydrochloride, Decitabine,

Withdrawn
  • Recurrent Acute Myeloid Leukemia
  • Refractory Acute Myeloid Leukemia
  • Alvocidib Hydrochloride
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Nov 9, 2020

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute

Terminated
Has Results
  • Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 29, 2020

Acute Bilineal Leukemia, Myelodysplastic/Myeloproliferative Tumor, Myelodysplastic/Myeloproliferative Tumor, Unclassifiable

Withdrawn
  • Acute Bilineal Leukemia
  • +11 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 12, 2020

Acute Myeloid Leukemia With FLT3/ITD Mutation, Recurrent Acute Myeloid Leukemia, Refractory Acute Leukemia Trial in Houston

Recruiting
  • Acute Myeloid Leukemia With FLT3/ITD Mutation
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
May 13, 2020

Acute Biphenotypic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid

Terminated
Has Results
  • Acute Biphenotypic Leukemia
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 5, 2019

Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial (Group 1: TK216, Group 2: TK216, Part 2: Decitabine

Withdrawn
  • Recurrent Acute Myeloid Leukemia
  • Refractory Acute Myeloid Leukemia
  • Group 1: TK216
  • +6 more
  • (no location specified)
May 2, 2019